Quick Links
The first FDA-authorized, non-invasive photobiomodulation (PBM) therapy for early to intermediate dry age-related macular degeneration (AMD).
How It Works
Valeda uses multi-wavelength light to stimulate retinal cells, boosting their natural energy production and slowing the cellular damage caused by dry AMD. This helps improve vision and slow disease progression without injections or surgery.
Treatment
A full course consists of 9 comfortable, in-office sessions completed over 3 to 5 weeks. Each visit is brief and non-invasive, with no downtime required.
Key Benefits
- First FDA-authorized PBM treatment for dry AMD
- Non-invasive with no needles or recovery time
- Stimulates retinal cells to improve and preserve vision
- Slows the progression of early to intermediate dry AMD